Roche Holding AG (RHHBY)
| Previous close | 37.79 |
| Open | 37.69 |
| Bid | 37.77 x 27000 |
| Ask | 37.78 x 40000 |
| Day's range | 37.50 - 37.81 |
| 52-week range | 29.20 - 42.43 |
| Volume | |
| Avg. volume | 1,724,900 |
| Market cap | 244.375B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 19.37 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.35 (3.57%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- GlobeNewswire
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritisGazyva/Gazyvaro is designed to target an underlying cause of lupus nephritis, aiming to prevent or delay progression to end-stage kidney disease1,2Lupus nephritis is a potentially life-threatening manifest
- Business Wire
Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
SOUTH SAN FRANCISCO, Calif., September 26, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva® (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated with Gazyva plus standard therapy (mycophenolate mofetil and glucocorticoids) achieved a complete renal response (CRR) at 76 weeks compared to those treated with standard therapy alone. Safet
- GlobeNewswire
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers cobas 5800, 6800 and 8800.TAGS has the potential to revolutionise testing for other infectious diseases in the future, by bringing high throughput customised syndromic panel testing to the routine clinical laboratory.The first TAGS-based test to be made available, the cobas Respiratory flex, offers
